Baxter International Inc. (NYSE:BAX) has received an average recommendation of “Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $65.42.

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald set a $70.00 price objective on shares of Baxter International and gave the company a “buy” rating in a report on Wednesday, July 26th. Cowen and Company reiterated a “market perform” rating and set a $68.00 price objective (up from $66.00) on shares of Baxter International in a report on Thursday, July 27th. Citigroup Inc. assumed coverage on shares of Baxter International in a report on Thursday, August 17th. They set a “neutral” rating and a $63.00 price objective for the company. Leerink Swann reiterated an “outperform” rating and set a $75.00 price objective (up from $67.00) on shares of Baxter International in a report on Thursday, July 27th. Finally, Zacks Investment Research cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/baxter-international-inc-bax-receives-average-recommendation-of-buy-from-analysts.html.

In other Baxter International news, Director Carole J. Shapazian sold 4,020 shares of Baxter International stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.61, for a total value of $247,672.20. Following the sale, the director now owns 13,868 shares of the company’s stock, valued at $854,407.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Giuseppe Accogli sold 12,670 shares of Baxter International stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $60.96, for a total transaction of $772,363.20. Following the completion of the sale, the senior vice president now directly owns 33,286 shares in the company, valued at approximately $2,029,114.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,050 shares of company stock worth $2,158,587. Insiders own 0.05% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Griffin Asset Management Inc. bought a new stake in Baxter International in the second quarter worth about $457,000. Achmea Investment Management B.V. raised its position in Baxter International by 15.3% in the second quarter. Achmea Investment Management B.V. now owns 94,282 shares of the medical instruments supplier’s stock worth $5,706,000 after acquiring an additional 12,537 shares during the period. USA Financial Portformulas Corp bought a new stake in Baxter International in the second quarter worth about $510,000. Farmers National Bank raised its position in Baxter International by 42.4% in the second quarter. Farmers National Bank now owns 8,408 shares of the medical instruments supplier’s stock worth $509,000 after acquiring an additional 2,502 shares during the period. Finally, Atlantic Trust LLC raised its position in Baxter International by 2.1% in the second quarter. Atlantic Trust LLC now owns 42,430 shares of the medical instruments supplier’s stock worth $2,609,000 after acquiring an additional 891 shares during the period. 83.71% of the stock is currently owned by institutional investors and hedge funds.

Baxter International (NYSE BAX) traded down 0.56% during trading on Friday, hitting $63.96. 4,525,594 shares of the stock were exchanged. The firm has a market cap of $34.85 billion, a PE ratio of 38.81 and a beta of 0.66. The firm’s 50-day moving average is $61.50 and its 200 day moving average is $57.69. Baxter International has a 52 week low of $43.13 and a 52 week high of $64.75.

Baxter International (NYSE:BAX) last issued its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.06. The firm had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The business’s revenue was up .8% on a year-over-year basis. During the same period last year, the company earned $0.46 earnings per share. Analysts expect that Baxter International will post $2.39 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 1st will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 1.00%. The ex-dividend date is Wednesday, August 30th. Baxter International’s dividend payout ratio (DPR) is presently 38.79%.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.